Melanoma is the deadliest form of skin cancer, yet early-stage disease is nearly always curable, making accurate automated detection a high-value clinical target. State-of-the-art deep-learning systems for dermoscopy analysis typically treat classification and segmentation as separate tasks and produce insufficient confidence scores, potentially limiting their safe deployment. We proposed DermFusion , which integrates both within a single ResNet-50+CBAM/ViT-B/16 dual-backbone network connected by a bidirectional cross-attention fusion layer. A U-Net decoder with Focal-Tversky deep supervision handles boundary prediction, while a Monte Carlo dropout head quantifies predictive uncertainty. Post-hoc temperature scaling calibrates model confidence, ensuring predicted probabilities better match actual accuracy. On the HAM10000 dataset, DermFusion achieves 87.82% accuracy, 0.9799 ROC-AUC, 0.9359 Dice, and 91.2% melanoma sensitivity. Calibration improves significantly, with the expected calibration error decreasing from 0.4395 to 0.1575, representing a 64.1% relative reduction. It has been observed that when an uncertainty-based referral threshold applies, 68% of cases classified autonomously reach 96.4% accuracy, with the remaining 32% flagged for expert review. external robustness evaluation on PH \(²\) , ISIC 2019, and PAD-UFES-20 datasets was applied, which shows that the combined representation works well across different acquisition domains. Ablation, fairness, and failure-mode studies characterize where and why the proposed DermFusion system succeeds or breaks down.
No takes yet. Share an insight, caveat, or question.
Yogesh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: